Company Filing History:
Years Active: 2025
Title: Yoon Lee - Innovator in Cancer Treatment
Introduction
Yoon Lee is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and development of chimeric antigen receptors.
Latest Patents
Yoon Lee holds a patent for a "Human anti-ANTXR chimeric antigen receptor and use thereof." This invention relates to a chimeric antigen receptor that specifically targets the anthrax toxin receptor (ANTXR). The patent includes a nucleic acid encoding a chimeric antigen receptor comprising a ligand PA63 that specifically binds to anthrax toxin receptor 1 (ANTXR1) or anthrax toxin receptor 2 (ANTXR2). Additionally, it covers a vector containing the nucleic acid, a recombinant cell comprising the vector, and a pharmaceutical composition for preventing or treating solid cancer. This innovative approach allows for the treatment of solid cancers, particularly in patients with pancreatic cancer, where traditional anti-cancer drugs may not be effective.
Career Highlights
Yoon Lee is associated with Mjcell Bio Co., Ltd., where he continues to advance his research in cancer therapies. His work focuses on developing customized treatments that are both efficient and safe for patients suffering from solid tumors.
Collaborations
Yoon collaborates with notable colleagues, including Kyung-Mi Lee and Seung-Hyun Jeon, to further enhance the impact of his research in the medical field.
Conclusion
Yoon Lee's innovative work in developing chimeric antigen receptors represents a significant advancement in cancer treatment. His contributions have the potential to improve the lives of many patients facing challenging diagnoses.